Coronary in-stent restenosis: Current status and future strategies

Journal of the American College of Cardiology

Volumn 39, Issue 2, 2002, Pages 183-193

  Lowe, Harry C ^a,b   Oesterle, Stephen N ^a   Khachigian, Levon M ^b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPEPTIN; ANTIINFLAMMATORY AGENT; ANTISENSE OLIGODEOXYNUCLEOTIDE; BATIMASTAT; COLCHICINE; DACTINOMYCIN; DEXAMETHASONE; DNA; GENE PRODUCT; METHYLPREDNISOLONE; PACLITAXEL; PROSTACYCLIN DERIVATIVE; PROTEIN LAC Z; RAPAMYCIN; RIBOZYME; UNCLASSIFIED DRUG; VASCULOTROPIN; VIRUS VECTOR;

ATHERECTOMY; CLINICAL TRIAL; CORONARY ARTERY OBSTRUCTION; CORONARY STENT; DRUG DELIVERY SYSTEM; DRUG EFFECT; ELECTRON THERAPY; GAMMA IRRADIATION; GENE DELIVERY SYSTEM; GENE TRANSFER; HISTOPATHOLOGY; HUMAN; IN STENT RESTENOSIS; INTIMA; NONHUMAN; PATHOGENESIS; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PRIORITY JOURNAL; RESTENOSIS; REVIEW; TREATMENT PLANNING;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANIMALS; ATHERECTOMY, CORONARY; CORONARY RESTENOSIS; DISEASE MODELS, ANIMAL; GENE TRANSFER TECHNIQUES; HUMANS; STENTS;

EID: 0037116569     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(01)01742-9     Document Type: Review

References (163)

1. Animal models of human coronary restenosis
2. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease: Stent restenosis study investigators
3. A comparison of balloon-expandable stent implantation with balloon angioplasty in patients with coronary artery disease: Benestent study group
4. Dramatic increase in the use of coronary stents
5. Improved in-hospital outcome with expanded use of coronary stents: Results from the NHLBI dynamic registry
6. Localized intracoronary gamma-radiation therapy to inhibit the recurrence of restenosis after stenting
7. Coronary artery stents
8. Real life stenting: A comparison of target vessel revascularization in Benestent-stress lesions to non-Benestent-stress lesions
9. Predictors of diffuse and aggressive intrastent restenosis
10. Angiographic patterns of in-stent restenosis: Classification and implications for long-term outcome
11. Histopathologic comparison of human coronary in-stent and post-balloon angioplasty restenotic tissue
12. Toward new therapeutic strategies against neointimal formation in restenosis
13. Arterial remodelling after coronary angioplasty: A serial intravascular ultrasound study
14. Serial follow-up after optimized ultrasound guided deployment of Palmaz-Schatz stents
15. Patterns and mechanisms of in-stent restenosis: A serial intravascular ultrasound study
16. Histopathology of in-stent restenosis in patients with peripheral artery disease
17. Acute and chronic tissue response to coronary stent implantation: Pathologic findings in human specimen
18. Pathology of in-stent restenosis
19. Morphological characteristics of lesion formation and time course of smooth muscle cell proliferation in a porcine proliferative restenosis model
20. The effects of uncontrolled hyperglycemia on thrombosis and formation of neointima after coronary stent placement in a novel diabetic porcine model of restenosis
21. Does thrombus contribute to in-stent restenosis in the porcine coronary stent model?
22. Pathology of acute and chronic coronary stenting in humans
23. The influence of diabetes mellitus on acute and late outcomes following coronary stent implantation
24. Comparison of outcome after stenting for de novo versus restenotic narrowings in native coronary arteries
25. Relation of a common methylenetetrahydrofolate reductase mutation and plasma homocysteine with intimal hyperplasia after coronary stenting
26. PIA polymorphism of platelet glycoprotein IIIa and risk of restenosis after coronary stent placement
27. Protective role against restenosis from an interleukin-receptor antagonist gene polymorphism in patients treated with coronary stenting
28. Genetic risk factors and restenosis after percutaneous coronary interventions
29. Nickel and molybdenum contact allergies in patients with coronary in-stent restenosis
30. Acute and long-term results of treatment of diffuse in-stent restenosls in aortocoronary saphenous vein grafts
31. Stented segment length as an independent predictor of restenosis
32. Vessel size and long-term outcome after coronary stent placement
33. Predictive factors of restenosis after coronary stent placement
34. Stenting In Chronic Coronary Occlusion (SICCO): A randomised, controlled trial of adding stent implantation after successful angioplasty
35. Risk factors for the development of restenosis following stent implantation of venous bypass grafts
36. Final results of the Can Routine Ultrasound Influence Stent Expansion (CRUISE) study
37. The utility of animal models in the preclinical study of interventions to prevent human coronary artery restenosis: On behalf of the Subcommittee on Animal, Cellular and Molecular Models of Thrombosis and Haemostasis of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis
38. Restenosis and the proportional neointimal response to coronary artery injury: Results in a porcine model
39. Site-specific dexamethasone delivery for the prevention of neointimal thickening after vascular stent placement
40. Short- and long-term histopathologic evaluation of stenting using a self-expanding nitinol stent in pig carotid and iliac arteries
41. A new rat model of small vessel stenting
42. Intra-arterial stenting in the atherosderotic rabbit
43. Reduction in thrombus formation by placement of endovascular stents at endarterectomy sites in baboon carotid arteries
44. Experimental models of coronary artery restenosis
45. Animal models and the study of atherosclerosis
46. Conjugated equine estrogens inhibit progression of atherosclerosis but have no effect on intimal hyperplasia or arterial remodelling induced by balloon catheter injury in monkeys
47. Time course of cellular proliferation, intimal hyperplasia, and remodelling following angioplasty in monkeys with established atherosclerosis: A nonhuman primate model of restenosis
48. Restenosis after balloon angioplasty: A practical proliferative model in porcine coronary arteries
49. Adjuvant therapy for intracoronary stents: Investigations in atherosclerotic swine
50. In-stent restenosis: Contributions of inflammatory responses and arterial injury to neointlma hyperplasia
51. Coronary in-stent restenosis - Predictors, treatment and prevention
52. Inhibition of neointima formation after experimental coronary stenting
53. Gene delivery from a DNA controlled-release stent in porcine coronary arteries
54. Yttrium-90 delivered via a centering catheter and afterloader, given both before and after stent implantation, inhibits neointima formation in porcine coronary arteries
55. Mechanisms and results of balloon angioplasty for the treatment of in-stent restenosis
56. Early lumen loss after treatment of in-stent restenosis
57. Intravascular ultrasound predictors of angiographic restenosis in lesions treated with Palmaz-Schatz stents
58. Stenting after Optimal Lesion Debulking (SOLD) registry
59. Directional atherectomy for treatment of restenosis within coronary stents: Clinical, angiographic and histologic results
60. Directional coronary atherectomy for the treatment of in-stent restenosis
61. Characteristics and consequences of myocardial infarction after percutaneous coronary intervention: Insights from the Coronary Angioplasty Versus Excisional Atherectomy Trial (CAVEAT)
62. Stent wire cutting during coronary directional atherectomy
63. Rotational atherectomy for in-stent restenosis: Acute and long-term results of the first 100 cases
64. Randomised Trial of Rotational Atherectomy versus Balloon Angioplasty for In-Stent Restenosis (ROSTER): Interim analysis of 150 cases
65. Rotational atherectomy or balloon angioplasty in the treatment of intra-stent restenosis: BARASTER multicenter registry
66. Long-term outcome of patients with proximal left anterior descending coronary artery in-stent restenosis treated with rotational atherectomy
67. Rotational atherectomy versus balloon angioplasty for diffuse in-stent restenosis: Preliminary results of a randomised multicentre trial (ARTIST trial)
68. Clinical and angiographic outcome in the Laser Angioplasty for Restenotic Stents (LARS) multicenter registry
69. Cutting balloon angioplasty for the treatment of in-stent restenosis
70. Cutting balloon angioplasty for the treatment of in-stent restenosis: A matched comparison with rotational atherectomy, additional stent implantation and balloon angioplasty
71. Final angiographic results of the restenosis intra-stent: Balloon angioplasty versus elective stenting (RIBS) randomised study
72. Treatment of focal in-stent restenosis with balloon angioplasty alone versus stenting: Short- and long-term results
73. New recipes for in-stent restenosis: Cut, grate, roast, or sandwich the neointima?
74. Stenting the stent: Initial results and long-term clinical and angiographic outcome of coronary stenting for patients with in-stent restenosis
75. Prevention of coronary restenosis: The evolving evidence base for radiation therapy
76. Intracoronary radiotherapy for restenosis
77. The relative radiosensitivity of the nucleus and cytoplasm of Chinese hamster fibroblasts
78. The treatment of 783 keloid scars by iridium 192 interstitial irradiation after surgical excision
79. Clinical trials of vascular brachytherapy for in-stent restenosis: Update
80. Intracoronary gamma-radiation therapy after angioplasty inhibits recurrence of in-patients with in-stent restenosis
81. Catheter-based radiotherapy to inhibit restenosis after coronary stenting
82. Inhibition of restenosis with beta-emitting radiotherapy: Report of the Proliferation Reduction with Vascular Energy Trial (PREVENT)
83. Short and intermediate term results of 32P radioactive beta-emitting stent implantation in patients with coronary artery disease
84. On the need for massive additional shielding of a catheterization laboratory for the implementation of high dose rate 192 Ir intravascular brachytherapy
85. Three-year clinical and angiographic follow-up after intracoronary radiation: Results of a randomised clinical trial
86. Beta-radiation to reduce restenosis: Too little, too soon?
87. Endoluminal beta-radiation therapy for the prevention of coronary restenosis after balloon angioplasty
88. Radioactive stents delay but do not prevent in-stent neointimal hyperplasia
89. Stent plus radiation: No sure cure for stenosis
90. Dosimetric considerations for catheter-based beta and gamma emitters in the therapy of neointimal hyperplasia in human coronary arteries
91. Intracoronary irradiation: Dose response for the prevention of restenosis in swine
92. Coronary artery disease following mediastinal radiation therapy
93. Edge stenosis and geographical miss following intracoronary gamma radiation therapy for in-stent restenosis
94. Serial intravascular ultrasound analysis of the impact of lesion length on the efficacy of intracoronary gamma irradiation for preventing recurrent in-stent restenosis
95. Geographic miss: A cause of treatment failure in radio-oncology applied to intracoronary radiation therapy
96. I like the candy, I hate the wrapper
97. Intracoronary beta-irradiation with a liquid (188)re-filled balloon: Six-month results from a clinical safety and feasibility study
98. Late coronary occlusion after inrracoronary brachytherapy
99. Prolonged antiplatelet therapy to prevent late thrombosis after intracoronary gamma-radiation in patients with in-stent restenosis: Washington Radiation for In-Stent Restenosis Trial plus 6 months of clopidogrel (WRIST PLUS)
100. The German IST-registry: Need of one year of clopidogrel to avoid late/late stent thrombosis
101. Prolonged antiplatelet therapy to reduce late thrombosis after intracoronary gamma radiation in patients with in-stent restenosis: "Plavix-wrist"
102. Late thrombosis after radiation: Sitting on a time bomb
103. Long-term angiographic and clinical outcome after percutaneous transluminal coronary angioplasty and intracoronary radiation therapy in humans
104. Coronary aneurysm five months after intracoronary beta-irradiation
105. "Black hole": Echolucent restenotic tissue after brachytherapy
106. Endovascular stent design dictates experimental restenosis and thrombosis
107. Restenosis after coronary placement of various stent types
108. Provisional stenting strategies: Systematic overview and implications for clinical decision making
109. Stent coatings and local drug delivery: State of the art
110. Marked inflammatory sequelae to implantation of biodegradable and nonbiodegradable polymers in porcine coronary arteries
111. Recent developments in coated stents
112. Lack of neointimal proliferation after implantation of sirolimus-coated stents in human coronary arteries
113. Drug eluting stents: A new era in the stent technology
114. Inhibition of intimal thickening after balloon angioplasty in porcine coronary arteries by targeting regulators of the cell cycle
115. Novel drug-delivery stent: Intravascular ultrasound observations from the first human experience with the QP-eluting polymer stent system
116. Antiproliferative approach to restenosis
117. Coated stents
118. Stent-based delivery is associated with marked spatial variations in drug distribution
119. Late acute thrombosis after paclitaxel eluting stent implantation
120. Restenosis: A challenge for pharmacology
121. Probucol and multivitamins in the prevention of restenosis after coronary angioplasty
122. Troglitazone reduces neointimal tissue proliferation after coronary stent implantation in patients with noninsulin dependent diabetes mellitus
123. TAS-301, an inhibitor of smooth muscle cell migration and proliferation, inhibits intimal thickening after balloon injury to rat carotid arteries
124. Inhibition of neointima formation by tranilast in pig coronary arteries after balloon angioplasty and stent implantation
125. The PRESTO (Prevention of Restenosis with Tranilast and its Outcomes) protocol: A double-blind, placebo-controlled trial
126. Evolution of nucleic acids as gene-specific targeting agents
127. Catalytic DNAs as potential therapeutic agents and sequence-specific molecular tools to dissect biologic function
128. An antisense oligonucleotide primer
129. Antisense c-myb oligonucleotides inhibit intimal smooth muscle cell accumulation in vivo
130. The effect of oligonucleotides to c-myb on vascular smooth muscle cell proliferation and neointima formation after porcine coronary angioplasty
131. Inhibition of smooth muscle cell proliferation in vivo following local delivery of antisense c-myb oligonucleotide during angioplasty
132. Local delivery of third-generation antisense drug inhibits neointimal formation after stent implantation in the porcine coronary artery
133. Antisense oligonucleotide against c-myc administered with the transport catheter for the prevention of in-stent restenosis: Results of the randomised ITALICS trial
134. Ribozymes and the anti-gene therapy: How a catalytic RNA can be used to inhibit gene function
135. Hammerhead ribozyme design and application
136. Adenovirus-mediated expression of a ribozyme to c-myb mRNA inhibits smooth muscle cell proliferation and neointima formation in vivo
137. Ribozyme oligonucleotides against transforming growth factor-B inhibited neointimal formation after vascular injury in the rat model
138. Chimeric DNA-RNA hammerhead ribozyme to proliferating cell nuclear antigen reduces stent-induced stenosis in a porcine coronary model
139. DNAzymes
140. Deoxyribozymes: New players in the ancient game of biocatalysis
141. Novel DNA enzyme targeting NGFI-A mRNA inhibits vascular smooth muscle proliferation and regrowth after injury
142. Catalytic oligodeoxynucleotides define a critical regulatory role for early growth response factor-1 in porcine coronary in-stent restenosis
143. Gene expression profiling of human stent-induced neointima by cDNA array analysis of microscopic specimens retrieved by helix cutter atherectomy: Detection of FK506-binding protein 12 upregulation
144. Gene therapy for restenosis: Are we ready?
145. Recombinant gene expression in vivo within endothelial cells of the arterial wall
146. Gene therapy in heart disease
147. Cardiovascular gene therapy
148. Gene therapy for restenosis: Promise and perils
149. Gene therapy for restenosis: Getting nearer the heart of the matter
150. Catheter-mediated vascular endothelial growth factor gene transfer to human coronary arteries after angioplasty
151. Adenoviruses as gene-delivery vehicles
152. Adventitial delivery minimizes the proinflammatory effects of adenoviral vectors
153. Adenovirus-modulated gene transfer into normal rabbit arteries results in prolonged vascular cell activation, inflammation and intimal hyperplasia
154. Thrombus generation after adenovirus-mediated gene transfer into atherosclerotic arteries
155. Gene therapy in the cardiovascular system: An update
156. Local drug delivery systems and prevention of restenosis
157. Percutaneous adenoviral gene transfer into porcine coronary arteries: Is catheter-based gene delivery adapted to coronary circulation?
158. Intravascular sonotherapy decreases neointimal hyperplasia after stent implantation in swine
159. Intravascular low-power red laser light as an adjunct to coronary stent implantation: Initial clinical experience
160. Ultrasound inhibits the adhesion and migration of smooth muscle cells in vitro
161. Ultrasound enhances reporter gene expression after transfection of vascular cells in vitro